L.A. Business Journal
DECEMBER 20, 2019
After several years of investing quietly, BAM Ventures is making some noise, generating headlines in November with its largest exit to date when Mid-Wilshire-based ecommerce software developer Honey Science Corp. was sold to Paypal Holdings Inc. for $4 billion.
socalTECH
DECEMBER 20, 2019
Our video interview today is with Brad Rice , the CEO and founder of Homepie (www.homepie.com), a very early stage startup working on a marketplace to buy and sell homes, without an agent. READ MORE>>.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
TechCrunch LA
DECEMBER 20, 2019
Burst , the subscription dental care service, with the pretty, pretty toothbrushes, has now added a sleek dental floss product to its monthly kits. The Los Angeles-based dental hygiene company, which has raised at least $20 million in financing from the growth capital investment firm Volition Capital, takes a different approach to reaching consumers than competitors like Quip.
L.A. Business Journal
DECEMBER 20, 2019
Although it takes place at the Las Vegas Convention Center, the 2020 Consumer Electronics Show is a key event for technology companies and startups based in Los Angeles.
Advertiser: Aggregage
Office leases are one of companies’ largest expenses, and if your whole team is working from home with no clear end in sight, you may be wondering what to do about your lease.
socalTECH
DECEMBER 20, 2019
Monrovia-based biopharmaceuticals developer Xencor announced on Friday morning that it has naed a new member of its board of directors. According to the company, it has appointed Dagmar Rosa-Bjorkeson, the former Executive Vice President and Chief Strategy and Development Officer at Mallinckrodt Pharmaceuticals to its board. Rosa-Bjorkeson also previously served at Baxalta, and also had served at Novartis for 17 years, serving is such roles as Vice President and Head of its multiple sclerosis bu
Xconomy
DECEMBER 20, 2019
As national politics dominates the news in the final days of the decade, we at Xconomy are wrapping up the year with some big moves by the FDA, including an approval of the first drug OK’d reduce heart risk in patients with high triglycerides who are already taking statins. Holidays don’t provide immunity to bad news, however, and some companies, like Gilead Sciences (NASDAQ: GILD ) and its investigational NASH drugs, didn’t get the clinical trial results they hoped for.
Startup Professionals Musings
DECEMBER 20, 2019
With the current strong economy I’m seeing a continued resurgence of entrepreneurial spirit, and more startup activity than ever before. I believe the days of the “job work” mentality are thankfully waning, with more people looking to get satisfaction by making the world a better place, rather than just tolerating brain-numbing work to fund enjoyment elsewhere.
Expert insights. Personalized for you.
173 
Let's personalize your content